ストックスクリーナーアプリを入手
45.68
3.39%
-1.58
前日終値:
$47.26
開ける：
$47.21
24時間の取引高:
617.65K
Relative Volume:
0.50
時価総額：
$4.03B
収益：
$170.10M
当期純損益:
$-239.59M
株価収益率:
-10.22
EPS:
-4.47
ネットキャッシュフロー:
$-191.20M
1週間 パフォーマンス:
-2.54%
1か月 パフォーマンス:
-5.88%
6か月 パフォーマンス:
-16.62%
1年 パフォーマンス:
-32.43%
1日の値動き範囲:
$45.51
$47.21
1週間の範囲:
$45.51
$48.44
52週間の値動き範囲:
$43.42
$91.10
Crispr Therapeutics Ag Stock (CRSP) Company Profile
CRSP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| CRSP | 45.66 | 4.03B | 170.10M | -239.59M | -191.20M | -4.47 |
| VRTX | 446.08 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 740.77 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.60 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.12 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.86 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2023-12-11 | ダウングレード | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | 開始されました | Mizuho | Buy |
| 2023-08-17 | アップグレード | Citigroup | Neutral → Buy |
| 2023-05-30 | 開始されました | William Blair | Outperform |
| 2023-04-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-03-21 | 開始されました | Bernstein | Mkt Perform |
| 2023-03-17 | 開始されました | Bryan Garnier | Buy |
| 2023-03-07 | 開始されました | Robert W. Baird | Neutral |
| 2022-10-11 | 開始されました | Morgan Stanley | Underweight |
| 2022-08-09 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2022-06-23 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-06-17 | 開始されました | BMO Capital Markets | Outperform |
| 2022-04-28 | 開始されました | Credit Suisse | Neutral |
| 2021-12-07 | 開始されました | Cowen | Market Perform |
| 2021-10-19 | 開始されました | SVB Leerink | Outperform |
| 2021-06-14 | アップグレード | Citigroup | Sell → Neutral |
| 2021-04-21 | アップグレード | Jefferies | Hold → Buy |
| 2021-03-04 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-12-10 | 繰り返されました | Chardan Capital Markets | Buy |
| 2020-12-10 | ダウングレード | Jefferies | Buy → Hold |
| 2020-12-10 | 繰り返されました | Needham | Buy |
| 2020-12-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | 開始されました | BofA Securities | Buy |
| 2020-07-28 | 繰り返されました | Needham | Buy |
| 2020-07-14 | 開始されました | SunTrust | Buy |
| 2020-06-15 | 繰り返されました | Canaccord Genuity | Buy |
| 2020-03-05 | 開始されました | Stifel | Hold |
| 2020-02-03 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-11-19 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | アップグレード | Oppenheimer | Perform → Outperform |
| 2019-08-01 | 開始されました | Jefferies | Buy |
| 2019-07-26 | 開始されました | Canaccord Genuity | Buy |
| 2019-06-10 | 開始されました | ROTH Capital | Buy |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-03-14 | 開始されました | William Blair | Mkt Perform |
| 2019-01-28 | ダウングレード | Goldman | Buy → Neutral |
| 2019-01-22 | ダウングレード | Citigroup | Neutral → Sell |
すべてを表示
Crispr Therapeutics Ag (CRSP) 最新ニュース
CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell? - Yahoo Finance
The Best Biotech Stocks to Buy - Morningstar
CRISPR Therapeutics AG (CRSP): Among the Best Genomics Stocks to Buy Right Now - Yahoo Finance
10 Best Genomics Stocks To Buy Right Now - Insider Monkey
CRISPR Therapeutics AG (NASDAQ:CRSP) Sees Large Increase in Short Interest - MarketBeat
CRISPR Therapeutics AG (CRSP): Among ARK Invest’s Top Stock Picks for 2024 - Insider Monkey
Is It Too Late to Buy Viking Therapeutics Stock? - The Motley Fool
2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More - Yahoo Finance
Gene Editing Tools Market Size, Growth Opportunities, - openPR
First Week of July 2025 Options Trading For CRISPR Therapeutics (CRSP) - Nasdaq
CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference - The Manila Times
Van ECK Associates Corp Sells 78,228 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Crispr therapeutics CEO Samarth Kulkarni sells shares worth $1.67 million - Investing.com India
Crispr therapeutics CEO Samarth Kulkarni sells shares worth $1.67 million By Investing.com - Investing.com UK
Sumitomo Mitsui Trust Group Inc. Has $139.44 Million Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Baillie Gifford & Co. Lowers Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics (CRSP) Stock Analysis: An Unexpected Rise Amidst A Flat Market - Barchart
CRISPR Therapeutics' SWOT analysis: gene editing pioneer faces casgevy launch challenges - Investing.com India
Crispr Therapeutics Q3 EarningsNo Casgevy Revenue, But Plenty Of Optimism (NASDAQ:CRSP) - Seeking Alpha
(CRSP) Investment Analysis - Stock Traders Daily
What is Chardan Capital's Estimate for CRSP FY2024 Earnings? - MarketBeat
CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates - MSN
What is Leerink Partnrs' Forecast for CRSP FY2024 Earnings? - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by ARK Investment Management LLC - MarketBeat
CRSP FY2024 EPS Reduced by Brookline Capital Management - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
CRSP's Q3 Loss Narrower Than Expected, Sales Miss Estimates - MSN
CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference - The Manila Times
Here's What Analysts Are Forecasting For CRISPR Therapeutics AG (NASDAQ:CRSP) After Its Third-Quarter Results - Simply Wall St
CRISPR Therapeutics AG (NASDAQ:CRSP) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance
CRISPR Therapeutics (NASDAQ:CRSP) Upgraded by StockNews.com to Sell Rating - MarketBeat
Positive Long-Term Outlook for Crispr Driven by Casgevy and Diverse Gene Editing Portfolio - Morningstar
Wall Street Analysts See a 62.75% Upside in CRISPR Therapeutics (CRSP): Can the Stock Really Move This High? - MSN
CRISPR Therapeutics Sell rating reiterated on recent performance - Investing.com
Barclays Has Lowered Expectations for CRISPR Therapeutics (NASDAQ:CRSP) Stock Price - MarketBeat
Leerink cuts CRISPR Therapeutics target to $67, keeps Outperform By Investing.com - Investing.com Canada
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results - GlobeNewswire
Leerink cuts CRISPR Therapeutics target to $67, keeps Outperform - Investing.com
CRISPR Therapeutics (CRSP) PT Lowered to $67 at Leerink Partners - StreetInsider.com
Crispr Therapeutics earnings beat by $0.41, revenue fell short of estimates - Investing.com
CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 4%Time to Sell? - MarketBeat
CRISPR Therapeutics AG Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
CRSPCRISPR Therapeutics AG Latest Stock News & Market Updates - StockTitan
CRISPR Q3: CASGEVY Expands Global Reach, $1.9B Cash Position as Losses Narrow | CRSP Stock News - StockTitan
CRISPR Therapeutics AG (CRSP) Just Overtook the 20-Day Moving Average - Zacks Investment Research
Crispr Therapeutics Ag (CRSP) 財務データ
収益
当期純利益
現金流量
EPS
0.42%
0.16%
大文字化:
|
ボリューム (24 時間):